Adage Capital Partners’s Bright Minds Biosciences DRUG Stock Holding History
Bought
Maintained
Sold
Other funds holding DRUG
Adage Capital Partners's DRUG Position: Q3 2026 in Review
Adage Capital Partners reduced its Bright Minds Biosciences (DRUG) stake by 3% in Q3 2026, selling an estimated $720K and leaving 324,800 shares worth $16.2M. The position accounts for 0.02% of the portfolio, ranked #593.
Adage Capital Partners first reported a position in DRUG in Q4 2024 and has held it in 8 quarters since. The position peaked at $36.2M in Q1 2026. 109 funds tracked by Wall St. Rank hold DRUG as of Q3 2026.
- Adage Capital Partners held 324,800 shares of Bright Minds Biosciences worth $16.2M as of Q3 2026.
- Adage Capital Partners sold 10,200 Bright Minds Biosciences shares in Q3 2026, an estimated $720K.
- Bright Minds Biosciences made up 0.02% of Adage Capital Partners's portfolio in Q3 2026, its #593 holding.
- Adage Capital Partners first reported a position in Bright Minds Biosciences in Q4 2024 and has held it in 8 quarters since.
- Adage Capital Partners's Bright Minds Biosciences position peaked at $36.2M in Q1 2026.
- 109 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q3 2026.
Based on Adage Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.